Federal Analysis
BARDA Procures TPOXX Antiviral from SIGA Technologies
March 11, 2026
SIGA Technologies, Inc. continues to secure procurement contracts with the Biomedical Advanced Research and Development Authority (BARDA) for its antiviral product TPOXXยฎ (Tecovirimat), supporting U.S. government efforts in biodefense and public health preparedness. The company's strong 2025 fiscal performance, driven by these government contracts and international sales, underscores the strategic importance of TPOXXยฎ in antiviral stockpiling and emergency response. Procurement professionals should note the ongoing reliance on SIGA as a prime contractor for antiviral therapies, highlighting opportunities and risks associated with single-product dependency and supply chain resilience.
- BARDA remains a key federal agency procuring TPOXXยฎ to bolster national biodefense capabilities.
- SIGA Technologies' role as prime contractor positions it as a critical supplier for antiviral stockpiles and emergency medical countermeasures.
- Procurement planning should consider the concentration risk due to reliance on a single antiviral product and the importance of maintaining a robust U.S.-based supply chain.
- Industry stakeholders may find opportunities in supporting supply chain diversification and complementary antiviral or biodefense products.
Agencies
Biomedical Advanced Research and Development Authority
Vendors
SIGA Technologies, Inc.